BioLife Solutions has undergone a strategic pivot, divesting freezer businesses to streamline into an asset-light consumables model, evidenced by debt falling to $15.7M and D/E of 0.04 in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.91+2812.0% vs $0.03 | $28M+2.4% vs $28M |
Q2 2026 May 7, 2026 | $0.04+300.0% vs $0.01 | $28M+7.2% vs $26M |
Q1 2026 Feb 26, 2026 | $0.04+300.0% vs -$0.02 | $25M+2.9% vs $24M |
Q4 2025 Nov 6, 2025 | $0.04+1900.0% vs $0.00 | $28M+9.4% vs $26M |
On October 23, 2026, BioLife Solutions Inc (BLFS) shares rose 3.5% to a current price of $38.61. The stock has shown a 52-week range between $17.86 and $39.76,
BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction.
Shares of BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report) have earned an average rating of "Hold" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial be
Benchmark BLFS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioLife Solutions, Inc. (BLFS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $38.61 | $1.89B | -154.44 | 16.97% | -12.61% | -3.37% | — | |
| $6.37 | $1.7B | -20.55 | 18.96% | -43.56% | -28.22% | — | |
| $39.16 | $1.8B | -32.10 | 3.55% | -20.02% | -7.56% | — | |
| $19.10 | $962.68M | 13.64 | -24.47% | -19.45% | -7.25% | — | |
| $173.49 | $9.79B | 201.73 | 16.36% | -1.47% | -0.56% | — | |
| $13.28 | $1.54B | -10.89 | 8.28% | -16.78% | -35.81% | — |
BioLife Solutions, Inc. (BLFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioLife Solutions, Inc. (BLFS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 3, 2026·SEC
Jul 22, 2026·SEC
Get notified when BLFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioLife Solutions, Inc. (BLFS) stock FAQ — growth, dividends, profitability & financials explained
BioLife Solutions, Inc. (BLFS) reported $102.8M in revenue over the trailing twelve months. Revenue was $96.2M in fiscal year 2025. That is 608% more than the $13.6M of fiscal year 1995.
BioLife Solutions, Inc. (BLFS) grew revenue by 17.0% in fiscal year 2025, compared with the prior fiscal year.
Yes. BioLife Solutions, Inc. (BLFS) earned $50.4M in net income over the trailing twelve months (a 49.1% net margin).
BioLife Solutions, Inc. (BLFS) had a return on equity (ROE) of -3.4% in fiscal year 2025. A negative ROE means the company lost money over the period.
BioLife Solutions, Inc. (BLFS) had negative free cash flow of $0.9M over the trailing twelve months.
